Boost Run, Inc. has had a remarkable month in price terms — yet the lending market tells a story of persistent bearish conviction that the rally has not yet shaken.
The stock closed at $28.43 on May 26, up 18% on the day and 68% over the past month. That is an extraordinary run for a small-cap athletic footwear name. But the short interest picture, as captured in recent ORTEX notes, remains elevated at approximately 32% of float — a level that tells you a substantial portion of the market is not buying the move.
The most telling signal in the lending market is the tension between availability and cost to borrow. Availability has actually loosened this week, recovering from a 52-week low of just 14.5% on May 18 — when only one share was available for every seven already borrowed — to around 40% now. That is still tight by any standard, but the direction matters: shares to borrow have become slightly more accessible as some shorts have unwound into the rally. Cost to borrow has followed the same trajectory, easing from a recent peak above 16% in mid-May to just over 9% now — still elevated, but moving in the direction you would expect when a heavily shorted name rallies hard and lenders get their collateral back. The lending pool spent several days last week at 100% utilisation — every available share out on loan — which represents the tightest borrow conditions of the past year.
Options positioning has grown more defensive in lockstep with the price move. The put/call ratio hit 0.62 on May 26, near its 52-week high of 0.63 recorded just the session before. Two weeks earlier the PCR was running at 0.15 — call buyers dominated as the stock started moving up. The steady climb in the PCR since early May suggests that as the rally extended, more participants began reaching for downside protection rather than adding to directional long exposure. That is a classic sign of a market that respects — but does not fully trust — the move.
The Street has shown some constructive moves. Craig-Hallum initiated coverage with a Buy and a $30 target on May 12, and DA Davidson followed on May 13, maintaining its Buy while raising its target to $25. Both targets were set when the stock was trading well below current levels, and with BRUN now at $28.43, the Craig-Hallum target has effectively been met. There is no current analyst consensus data available beyond these two names, and the institutional holder base is thin — Citadel Advisors holds around 2.7% of shares, with Harilaos Georgakopoulos disclosed at 12.4% via a May 8 filing. With only three reported institutional holders and no fresh analyst revisions post-rally, the Street has not yet publicly updated its view to reflect the new price level. A previous ORTEX score note from mid-May had BRUN at 42 out of 100, trailing peers in the athletic footwear space who were averaging scores in the mid-50s — though that reading preceded much of the recent price appreciation.
What to watch next: whether analyst coverage updates their targets in response to the 68% monthly gain, and whether availability continues to loosen or reverts toward the sub-20% levels seen in mid-May — a tightening back toward those lows would signal shorts rebuilding into strength.
See the live data behind this article on ORTEX.
Open BRUN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
